Analyst Consensus ?
ConsensusBuy42 ratings
Bullish3378.6%
Neutral921.4%
Bearish00.0%
Abbott Laboratories · ABT · FY2025 Q2 · Calendar Q3 2025
Abbott maintains guidance as medical devices drive Q2 growth
The supplied analysis supports a mixed but constructive view: medical-device growth and a broad product pipeline provide evidence for durable demand, while diagnostic weakness, tariffs, China pricing, regulation, and CGM competition are important counterweights.
Reported Before market openNYSEHealthcare
$169.87B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.26
Consensus $1.26
EPS surprise
0.0%
Reported versus consensus
Reported revenue
$11.14B
Consensus $11.09B
Revenue surprise
+0.5%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-8.5%
Event window
SPY move
+0.6%
Same window
Abnormal move
-9.1%
Stock minus SPY
Volume
4.3×
Versus trailing sessions
Subsequent drift
+7.3%
Up to 20 sessions
ABTSPY benchmark
Ask FN2 about ABT FY2025 Q2
Transcript, numbers and history already loaded
Why did ABT fall 8.5% after beating EPS estimates in FY2025 Q2?What changed in ABT's guidance and outlook in FY2025 Q2?Give me the bull and bear case for ABT after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the current quarter shows continued high-single-digit organic growth and maintained guidance, with Medical Devices strengthening to 12% growth while Diagnostics remained under pressure from COVID-test declines and China procurement. The current analysis also emphasizes the Epic-Libre integration, biosimilar submissions, and the planned Tendyne pivotal trial.
Guidance delta
Maintained: full-year guidance remained unchanged, with high single-digit sales growth and double-digit EPS growth expected.
Key takeaways
- Q2 organic sales growth excluding COVID testing was 7.5%, with double-digit EPS growth.
- Medical Devices grew 12%, led by diabetes CGM, electrophysiology, and structural heart products.
- Diagnostics declined modestly amid COVID-test pullback and China procurement pressure; core lab outside China grew 8%.
- Management highlighted Libre, Volt, structural heart products, biosimilars, and branded generics as growth drivers.
Management priorities
- Expand Libre CGM adoption and its Epic electronic-health-record integration
- Advance Volt, MitraClip, Tendyne, and other structural-heart and electrophysiology programs
- Roll out biosimilars and branded generics in emerging markets
- Build U.S. cardiovascular manufacturing capacity
Follow ABT with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$98.16Previous close
$92Low
$131.6Average
$165.65High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 7, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Rothschild & Co | Buy | Neutral | Upgrade | Oct 2, 2026 |
| TD Cowen | Buy | Buy | Maintain | Sep 8, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 14, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 13, 2026 |
| UBS | Buy | Buy | Maintain | Jul 28, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 17, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 17, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 17, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 17, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 17, 2026 |
| BTIG | Buy | Buy | Maintain | Jul 17, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | May 31, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 20, 2026 |
| Stifel | Buy | Buy | Maintain | Apr 17, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Apr 17, 2026 |
| Benchmark | Buy | Buy | Maintain | Apr 17, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 17, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Jan 29, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jan 23, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Oct 16, 2025 |
| Mizuho | Neutral | Neutral | Maintain | Jul 18, 2025 |
| Jefferies | Buy | Hold | Upgrade | Jul 18, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 15, 2025 |
| Argus Research | Buy | Buy | Maintain | Jul 28, 2022 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Apr 21, 2022 |
| CFRA | Buy | Buy | Maintain | Apr 20, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Jan 27, 2022 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Oct 27, 2021 |
| Cowen & Co. | Outperform | Outperform | Maintain | Jan 28, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jan 23, 2020 |
| Guggenheim Securities | Neutral | Buy | Downgrade | Jan 2, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Jan 2, 2020 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 18, 2019 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| William Blair | Outperform | Market Perform | Upgrade | Jan 25, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Jan 22, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 21, 2017 |
| Edward Jones | Buy | Hold | Upgrade | Jun 21, 2016 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 28, 2016 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 25, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | May 21, 2013 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 5, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $98.16. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $120 | $98.17 | +22.2% | Oct 6, 2026 |
| Redburn Partners | Ed Ridley-Day | $127 | $96.71 | +29.4% | Oct 2, 2026 |
| Wolfe Research | Analyst unavailable | $130 | $110.92 | +32.4% | Aug 13, 2026 |
| UBS | Patrick Wood | $125 | $108.84 | +27.3% | Jul 28, 2026 |
| Benchmark Co. | Analyst unavailable | $120 | $100.67 | +22.2% | Jul 20, 2026 |
| Piper Sandler | Analyst unavailable | $118 | $98.82 | +20.2% | Jul 17, 2026 |
| BTIG | Analyst unavailable | $134 | $98.82 | +36.5% | Jul 16, 2026 |
| Evercore ISI | Vijay Kumar | $112 | $93.64 | +14.1% | Jul 6, 2026 |
| Robert W. Baird | David Rescott | $121 | $90.68 | +23.3% | Jun 30, 2026 |
| Daiwa | Analyst unavailable | $92 | $92.74 | -6.3% | Apr 22, 2026 |
| Barclays | Matt Miksic | $143 | $96.83 | +45.7% | Apr 20, 2026 |
| UBS | Analyst unavailable | $115 | $95.46 | +17.2% | Apr 17, 2026 |
| Piper Sandler | Analyst unavailable | $115 | $95.46 | +17.2% | Apr 17, 2026 |
| Stifel Nicolaus | Analyst unavailable | $120 | $95.46 | +22.2% | Apr 17, 2026 |
| UBS | Danielle Antalffy | $158 | $108.42 | +61.0% | Mar 13, 2026 |
| New Street | Analyst unavailable | $145 | $108.14 | +47.7% | Mar 13, 2026 |
| Barclays | Analyst unavailable | $142 | $109.3 | +44.7% | Feb 2, 2026 |
| Loop Capital Markets | Ilya Zubkov | $120 | $106.09 | +22.2% | Jan 29, 2026 |
| Evercore ISI | Analyst unavailable | $138 | $108.61 | +40.6% | Jan 23, 2026 |
| UBS | Analyst unavailable | $132 | $108.6 | +34.5% | Jan 23, 2026 |
| Mizuho Securities | Anthony Petrone | $125 | $108.6 | +27.3% | Jan 23, 2026 |
| Piper Sandler | Analyst unavailable | $135 | $108.6 | +37.5% | Jan 23, 2026 |
| Bernstein | Analyst unavailable | $125 | $108.6 | +27.3% | Jan 23, 2026 |
| Wells Fargo | Larry Biegelsen | $122 | $108.6 | +24.3% | Jan 23, 2026 |
| Bernstein | Lee Hambright | $154 | $126.18 | +56.9% | Jan 9, 2026 |
| Goldman Sachs | Analyst unavailable | $152 | $126.18 | +54.8% | Jan 9, 2026 |
| Evercore ISI | Analyst unavailable | $144 | $123.97 | +46.7% | Jan 5, 2026 |
| Barclays | Analyst unavailable | $169 | $124.19 | +72.2% | Jan 5, 2026 |
| BTIG | Marie Thibault | $145 | $126.24 | +47.7% | Dec 22, 2025 |
| Tigress Financial | Analyst unavailable | $145 | $128.12 | +47.7% | Nov 21, 2025 |
| Barclays | Analyst unavailable | $162 | $127.63 | +65.0% | Oct 17, 2025 |
| Wells Fargo | Analyst unavailable | $146 | $129.45 | +48.7% | Oct 16, 2025 |
| Goldman Sachs | Analyst unavailable | $157 | $133.94 | +59.9% | Oct 1, 2025 |
| RBC Capital | Shagun Singh | $147 | $131.49 | +49.8% | Jul 15, 2025 |
| RBC Capital | Shagun Singh | $140 | $126.22 | +42.6% | Apr 15, 2025 |
| Bernstein | Lee Hambright | $135 | $114.25 | +37.5% | Jan 8, 2025 |
| Piper Sandler | Adam Maeder | $133 | $117.82 | +35.5% | Oct 17, 2024 |
| Bernstein | Lee Hambright | $138 | $117.82 | +40.6% | Oct 17, 2024 |
| Jefferies | Matthew Taylor | $125 | $117.82 | +27.3% | Oct 16, 2024 |
| Evercore ISI | Vijay Kumar | $128 | $117.82 | +30.4% | Oct 16, 2024 |
| BTIG | Marie Thibault | $139 | $117.82 | +41.6% | Oct 16, 2024 |
| Oppenheimer | Suraj Kalia | $130 | $114.3 | +32.4% | Oct 8, 2024 |
| RBC Capital | Shagun Singh | $130 | $113.36 | +32.4% | Oct 8, 2024 |
| RBC Capital | Jonathan Atkin | $165.65 | $54.49 | +68.8% | Sep 19, 2024 |
| Piper Sandler | Adam Maeder | $131 | $114.88 | +33.5% | Sep 19, 2024 |
| Jefferies | Matthew Taylor | $120 | $112.22 | +22.2% | Aug 27, 2024 |
| Citigroup | Joanne Wuensch | $127 | $111.39 | +29.4% | Aug 22, 2024 |
| Citigroup | Joanna Wiensch | $119 | $104.68 | +21.2% | Jul 18, 2024 |
| Evercore ISI | Vijay Kumar | $120 | $103.2 | +22.2% | Jul 2, 2024 |
| BTIG | Marie Thibault | $135 | $102.99 | +37.5% | Jun 3, 2024 |
| Goldman Sachs | David Roman | $121 | $100.73 | +23.3% | May 30, 2024 |
| Barclays | Matt Miksic | $140 | $107.07 | +42.6% | Apr 22, 2024 |
| Bernstein | Lee Hambright | $133 | $105.27 | +35.5% | Apr 18, 2024 |
| RBC Capital | Shagun Singh | $125 | $105.9 | +27.3% | Apr 18, 2024 |
| Morgan Stanley | Analyst unavailable | $133 | $111.37 | +35.5% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $125 | $107.51 | +27.3% | Dec 12, 2022 |
| RBC Capital | Shagun Singh | $132 | $109.78 | +34.5% | Aug 3, 2022 |
| UBS | Analyst unavailable | $128 | $109.09 | +30.4% | Jul 27, 2022 |
| Citigroup | Analyst unavailable | $123 | $108.23 | +25.3% | Jul 21, 2022 |
| BTIG | Analyst unavailable | $126 | $108.36 | +28.4% | Jul 18, 2022 |
| Stifel Nicolaus | Analyst unavailable | $126 | $108.43 | +28.4% | Jul 18, 2022 |
| Raymond James | Analyst unavailable | $117 | $105.71 | +19.2% | Jul 15, 2022 |
| BTIG | Marie Thibault | $130 | $109.45 | +32.4% | Jun 27, 2022 |
| Raymond James | Jayson Bedford | $135 | $119.64 | +37.5% | Apr 25, 2022 |
| RBC Capital | Analyst unavailable | $143 | $122.64 | +45.7% | Apr 21, 2022 |
| BTIG | Marie Thibault | $140 | $123.8 | +42.6% | Apr 21, 2022 |
| New Street | Analyst unavailable | $117.49 | $123.41 | +19.7% | Apr 20, 2022 |
| Wells Fargo | Larry Biegelsen | $150 | $120.04 | +52.8% | Apr 11, 2022 |
| Bank of America Securities | Travis Steed | $140 | $120.97 | +42.6% | Mar 3, 2022 |
| Morgan Stanley | Cecilia Furlong | $151 | $122.41 | +53.8% | Feb 26, 2022 |
| Raymond James | Jayson Bedford | $143 | $129.71 | +45.7% | Feb 6, 2022 |
| Citigroup | Joanne Wuensch | $154 | $135.08 | +56.9% | Dec 15, 2021 |
| Jefferies | Raj Denhoy | $145 | $124.61 | +47.7% | Oct 21, 2021 |
| Stifel Nicolaus | Rick Wise | $130 | $117.38 | +32.4% | Jul 22, 2021 |
| Goldman Sachs | Amit Hazan | $120 | $104.61 | +22.2% | Jun 1, 2021 |
| Evercore ISI | Vijay Kumar | $136 | $121.24 | +38.5% | Apr 21, 2021 |
Track every rating change on ABT the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAbbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools.…
Historical context
All ABT earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- LWFY2027 Q1 · October 6, 2026+27.8% EPS+7.5% move
- RPMFY2027 Q1 · October 6, 2026+1.5% EPS+3.2% move
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
Get the ABT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-07T05:50:43.715895+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-07T05:50:43.713172+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-07. For educational purposes only; not investment advice.